ENvue Medical, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $2.6M | $2.3M | $752.0K | $1.7M | $623.0K | $530.0K | $318.0K |
| Cost of Revenue | $2.4M | $1.1M | $746.0K | $585.0K | $925.0K | $409.0K | $249.0K | $158.0K |
| Gross Profit | $153.0K | $1.5M | $1.5M | $167.0K | $770.0K | $214.0K | $281.0K | $160.0K |
| Gross Margin | 6.0% | 59.0% | 67.3% | 22.2% | 45.4% | 34.3% | 53.0% | 50.3% |
| Operating Expenses | ||||||||
| Research & Development | $1.8M | $909.0K | $185.0K | $283.0K | $293.0K | $171.0K | $514.0K | $614.0K |
| SG&A Expense | $7.6M | $3.5M | $3.9M | $3.9M | $5.1M | $3.8M | $3.8M | $2.6M |
| Operating Income | $-22.9M | $-3.6M | $-3.4M | $-5.0M | $-5.7M | $-4.7M | $-5.2M | $-4.3M |
| Operating Margin | -896.6% | -140.0% | -150.5% | -666.5% | -335.3% | -757.5% | -971.9% | -1,353.1% |
| Interest Expense | — | $135.0K | $135.0K | $347.0K | — | $147.0K | $15.0K | — |
| Pretax Income | $-18.5M | $-3.7M | $-3.7M | $-5.4M | $-14.3M | $-4.3M | $-5.8M | $-4.3M |
| Income Tax Expense | $-307.0K | $19.0K | $29.0K | $35.0K | $32.0K | $15.0K | $-17.0K | $-127.0K |
| Net Income | $-18.2M | $-3.7M | $-3.7M | $-5.4M | $-14.3M | $-4.3M | $-5.8M | $-4.2M |
| Net Margin | -712.3% | -144.8% | -162.5% | -724.5% | -842.6% | -694.4% | -1,093.2% | -1,306.3% |
| EPS (Basic) | $-26.69 | $-5.97 | $-1.01 | $-0.17 | $-0.49 | $-0.02 | $-0.04 | $-0.03 |
| EPS (Diluted) | $-26.69 | $-5.97 | $-1.01 | $-0.17 | $-0.02 | $-0.02 | $-0.04 | $-0.03 |
| Shares Outstanding (Basic) | 628.5K | 620.7K | 3.7M | 32.7M | 28.9M | 488.7M | 96.7M | 87.4M |
| Shares Outstanding (Diluted) | 628.5K | 620.7K | 3.7M | 32.7M | 28.9M | 488.7M | 96.7M | 87.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |